DDIT3 and non-Hodgkin lymphoma: Given the high rate of disease progression during standard CHOP chemotherapy (35%) as well as the previously documented superiority of CHOP-14 over standard CHOP by the German high-grade NHL study group [45, 46], two cycles of dose-intense CHOP every two weeks (DI-CHOP-14) followed by RT and consolidation therapy with four cycles of standard CHOP thereafter was investigated by Kim et al. and Lee et al. in patients with localized nasal NK/T-cell NHL [18, 47].